The extension to the licence follows the results of a multi-centre clinical trial in which it was shown that docetaxel
in combination with cisplatin and 5-FU produced a significantly longer time to progression of the disease and a significant reduction in mortality compared to cisplatin and 5-FU alone.
Patients must be adequately hydrated, be premedicated with antiemetics and receive prophylactic G-CSF to mitigate the risk of haematological toxicities.Further information:
Sanofi Aventis, 1 Onslow Street, Guildford, Surrey GU1 4YS. Tel: (01483) 505515.